Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Zelicapavir

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Enanta Pharma Shares Zelicapavir RSV Data at ESCMID
    Enanta Pharma Shares Zelicapavir RSV Data at ESCMID

    07 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-07/enanta-pharmaceuticals-to-present-data-for-zelicapavir-an-oral-once-daily-n-protein-inhibitor-in

    PHARMIWEB
    07 Apr 2026
    Share Share
    Enanta Pharma Discloses Q1 Fiscal Results Ended Dec 31, 2025
    Enanta Pharma Discloses Q1 Fiscal Results Ended Dec 31, 2025

    09 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260209293558/en/Enanta-Pharmaceuticals-Reports-Financial-Results-for-its-Fiscal-First-Quarter-Ended-December-31-2025

    BUSINESSWIRE
    09 Feb 2026
    Share Share
    Enanta Pharma Updates Research Programs & 2026 Outlook
    Enanta Pharma Updates Research Programs & 2026 Outlook

    08 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-08/enanta-pharmaceuticals-provides-update-on-its-research-and-development-programs-and-2026-outlook

    PHARMIWEB
    08 Jan 2026
    Share Share
    Enanta Pharma Unveils Zelicapavir And EDP-323, Data For RSV
    Enanta Pharma Unveils Zelicapavir And EDP-323, Data For RSV

    20 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251020795690/en/Enanta-Pharmaceuticals-Presents-New-Data-for-Zelicapavir-its-N-Protein-Inhibitor-and-EDP-323-its-L-Protein-Inhibitor-Both-in-Development-for-the-Treatment-of-Respiratory-Syncytial-Virus-RSV-at-IDWeek-2025

    BUSINESSWIRE
    20 Oct 2025
    Share Share
    Enanta To Present Zelicapavir, EDP-323 RSV Data At IDWeek 2025
    Enanta To Present Zelicapavir, EDP-323 RSV Data At IDWeek 2025

    07 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-07/enanta-pharmaceuticals-to-present-data-for-zelicapavir-and-edp-323-two-candidates-in-development-fo

    PHARMIWEB
    07 Oct 2025
    Share Share
    Enanta To Share Ph 2b Zelicapavir Results In RSV High-Risk Adults
    Enanta To Share Ph 2b Zelicapavir Results In RSV High-Risk Adults

    26 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250926821731/en/Enanta-Pharmaceuticals-to-Present-Topline-Results-from-its-Phase-2b-Study-Evaluating-Zelicapavir-for-the-Treatment-of-Respiratory-Syncytial-Virus-RSV-in-High-Risk-Adults

    BUSINESSWIRE
    26 Sep 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.